January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
1 citations
,
April 2019 in “Reumatología Clínica (English Edition)” Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
May 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.
Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
1 citations
,
October 2015 in “The American journal of gastroenterology” Stopping infliximab and using strong topical steroids can regrow hair lost due to psoriasiform alopecia.
December 2024 in “PubMed” Cyclosporine effectively treated a woman's stubborn skin condition.
April 2023 in “Journal of Investigative Dermatology” CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.
1 citations
,
March 2022 in “JAAD case reports” Methotrexate injection site reactions are rare but can be managed by changing injection sites and using topical treatments.
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
42 citations
,
March 2015 in “Anais Brasileiros de Dermatologia” Anti-TNF therapy can cause hair loss and skin issues.
3 citations
,
November 2023 in “Journal of Investigative Dermatology” Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
3 citations
,
October 2024 in “Cancers” Skin side effects from melanoma immunotherapy are common and may indicate better survival.
53 citations
,
July 2009 in “Cancer Research” Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
9 citations
,
May 2005 in “Expert Review of Clinical Immunology” Blocking interferon-gamma might help treat various autoimmune diseases.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
Intralesional methotrexate effectively treats alopecia areata by reducing TNF-α levels, leading to hair regrowth.
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
1 citations
,
August 2024 in “British Journal of Dermatology” Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.
1 citations
,
August 1983 in “PubMed” CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.